NB
CRSP icon

NBT Bank’s CRISPR Therapeutics CRSP Stock Holding History

NBT Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109 Hold
2
– – ﹤0.01% 1054
2026
Q1 		$95 Hold
2
– – ﹤0.01% 1042
2025
Q4 		$105 Hold
2
– – ﹤0.01% 807
2025
Q3 		$130 Hold
2
– – ﹤0.01% 800
2025
Q2 		$97 Hold
2
– – ﹤0.01% 784
2025
Q1 		$68 Hold
2
– – ﹤0.01% 796
2024
Q4 		$79 Hold
2
– – ﹤0.01% 769
2024
Q3 		$94 Buy
+2
New +$101 ﹤0.01% 816

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NBT Bank's CRSP Position: Q2 2026 in Review

NBT Bank held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 2 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #1054.

NBT Bank first reported a position in CRSP in Q3 2024 and has held it in 8 quarters since. The position peaked at $130 in Q3 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • NBT Bank held 2 shares of CRISPR Therapeutics worth $109 as of Q2 2026.
  • NBT Bank left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of NBT Bank's portfolio in Q2 2026, its #1054 holding.
  • NBT Bank first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • NBT Bank's CRISPR Therapeutics position peaked at $130 in Q3 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on NBT Bank's 13F filing for Q2 2026, filed 29 Jul 2026.